Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 9/2010

01-09-2010 | Original Paper

Selective inhibition of human leukemia cell growth and induction of cell cycle arrest and apoptosis by pseudolaric acid B

Authors: Guoyi Ma, Li Chong, Xing-Cong Li, Ikhlas A. Khan, Larry A. Walker, Shabana I. Khan

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2010

Login to get access

Abstract

Purpose

The leukemias account for the largest number of cases of childhood cancer and remain the primary cause of cancer-related mortality among children in the United States. There is a need for novel antileukemia agents due to toxicity and resistant to existing chemotherapeutic agents. In this study, the effects of pseudolaric acid B (PAB) on three human leukemia cell lines, acute promyelocytic leukemia HL-60 cells, acute lymphoblastic leukemia CCRF-CEM cells, and human chronic myeloid leukemia blast-phase K562 cells were investigated in vitro, compared to normal human peripheral blood mononuclear cells (PBMC).

Methods

Cell viability was determined using CellTiter-Glo luminescent reagent. Colony formation was assessed by Microtitration cloning assay. Cell cycle analysis was carried out by flow cytometry. Tubulin polymerization was measured by recording the increase in absorbance. Inhibition of topoisomerase I (topo I) and topoisomerase II (topo II) enzyme activities was measured by DNA relaxation assay using topo I and II drug screening kit. Apoptosis was observed by DAPI staining assay and Caspase3/7 activities was measured using Caspase-Glo® 3/7 assay kit.

Results

Pseudolaric acid B selectively inhibited the growth of human leukemia HL-60, CCRF-CEM and K562 cells, but not normal PBMC. PAB suppressed colony formation in HL-60 cells. Cell cycle analysis showed that PAB blocked the cell cycle at G2/M phase in HL-60 cells, suggesting that it suppresses mitosis. DNA topo I and topo II were not inhibited, but tubulin polymerization was inhibited. PAB-induced apoptosis and activated caspase-3/7 activity.

Conclusions

This study indicates that PAB has a potential for use against leukemia and its effects might be mediated by inhibiting tubulin polymerization, preventing cell division and activating caspase-3, which leads to apoptosis.
Literature
go back to reference Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 326:1–16PubMed Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 326:1–16PubMed
go back to reference Gerber DE (2008) Targeted therapies: a new generation of cancer treatments. Am Fam Physician 77:311–319PubMed Gerber DE (2008) Targeted therapies: a new generation of cancer treatments. Am Fam Physician 77:311–319PubMed
go back to reference Gong XF, Wang MW, Wu Z, Tashiro S, Onodera S, Ikejima T (2004) Pseudolaric acid B induces apoptosis via activation of c Jun N-terminal kinase and caspase-3 in hela cells. Exp Mol Med 31:551–556 Gong XF, Wang MW, Wu Z, Tashiro S, Onodera S, Ikejima T (2004) Pseudolaric acid B induces apoptosis via activation of c Jun N-terminal kinase and caspase-3 in hela cells. Exp Mol Med 31:551–556
go back to reference Gong XF, Wang MW, Tashiro S, Onodera S, Ikejima T (2005a) Pseudolaric acid B induces apoptosis through P53 and Bax/Bcl-2 Pathways in human melanoma A 375-S2 cells. Arch Pharm Res 28:68–72. doi:10.1007/BF02975138 CrossRefPubMed Gong XF, Wang MW, Tashiro S, Onodera S, Ikejima T (2005a) Pseudolaric acid B induces apoptosis through P53 and Bax/Bcl-2 Pathways in human melanoma A 375-S2 cells. Arch Pharm Res 28:68–72. doi:10.​1007/​BF02975138 CrossRefPubMed
go back to reference Gong XF, Wang MW, Tashiro S, Onodera S, Ikejima T (2005b) Pseudolaric acid B induces human melanoma A 375-S2 cell apoptosis in vitro. Zhongguo Zhong Yao Za Zhi 30:55–57PubMed Gong XF, Wang MW, Tashiro S, Onodera S, Ikejima T (2005b) Pseudolaric acid B induces human melanoma A 375-S2 cell apoptosis in vitro. Zhongguo Zhong Yao Za Zhi 30:55–57PubMed
go back to reference Jordan MA (2002) Mechanism of action of anticancer drugs that interact with microtubule and tubulin. Curr Med Chem Anticancer Agents 2:1–17CrossRefPubMed Jordan MA (2002) Mechanism of action of anticancer drugs that interact with microtubule and tubulin. Curr Med Chem Anticancer Agents 2:1–17CrossRefPubMed
go back to reference Jordan MA, Thrower D, Wilson L (1991) Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 51:2212–2221PubMed Jordan MA, Thrower D, Wilson L (1991) Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 51:2212–2221PubMed
go back to reference Khan SI, Nimrod AC, Mehrpooya M, Nitiss JL, Walker LA, Clark AM (2002) Antifungal activity of eupolauridine and its action on DNA topoisomerases. Antimicrob Agents Chemother 46:1785–1792CrossRefPubMed Khan SI, Nimrod AC, Mehrpooya M, Nitiss JL, Walker LA, Clark AM (2002) Antifungal activity of eupolauridine and its action on DNA topoisomerases. Antimicrob Agents Chemother 46:1785–1792CrossRefPubMed
go back to reference Li KS, Gu XF, Li P, Zhang Z, Zhao YS, Yao ZJ, Qu NQ, Wang BY (2005) Effect of pseudolaric acid B on gastric cancer cells: inhibition of proliferation and induction of apoptosis. World J Gastroenterol 11:7555–7559PubMed Li KS, Gu XF, Li P, Zhang Z, Zhao YS, Yao ZJ, Qu NQ, Wang BY (2005) Effect of pseudolaric acid B on gastric cancer cells: inhibition of proliferation and induction of apoptosis. World J Gastroenterol 11:7555–7559PubMed
go back to reference Pan D, Li ZL, Hu CQ, Chen K, Chang JJ, Lee KH (1990) Antitumor agents: 109. The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid A and B and related derivatives. Planta Med 56:383–385. doi:10.1055/s-2006-960989 CrossRefPubMed Pan D, Li ZL, Hu CQ, Chen K, Chang JJ, Lee KH (1990) Antitumor agents: 109. The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid A and B and related derivatives. Planta Med 56:383–385. doi:10.​1055/​s-2006-960989 CrossRefPubMed
go back to reference Shi Q, Chen KC, Morrist-Natschke SL, Lee KH (1998) Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Curr Pharm Des 4:219–248PubMed Shi Q, Chen KC, Morrist-Natschke SL, Lee KH (1998) Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Curr Pharm Des 4:219–248PubMed
go back to reference Wong VKW, Chiu P, Chung SSM, Chow LMC, Zhao YZ, Yang BB, Ko BCB (2005) Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 11:6002–6011. doi:10.1158/1078-0432.CCR-05-0209 CrossRefPubMed Wong VKW, Chiu P, Chung SSM, Chow LMC, Zhao YZ, Yang BB, Ko BCB (2005) Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 11:6002–6011. doi:10.​1158/​1078-0432.​CCR-05-0209 CrossRefPubMed
go back to reference Zhang YL, Lu RZ, Yan AL (1990) Inhibition of ova fertilizability by pseudolaric acid B in hamster. Acta Pharmacol Sin 11:60–62 Zhang YL, Lu RZ, Yan AL (1990) Inhibition of ova fertilizability by pseudolaric acid B in hamster. Acta Pharmacol Sin 11:60–62
Metadata
Title
Selective inhibition of human leukemia cell growth and induction of cell cycle arrest and apoptosis by pseudolaric acid B
Authors
Guoyi Ma
Li Chong
Xing-Cong Li
Ikhlas A. Khan
Larry A. Walker
Shabana I. Khan
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0784-0

Other articles of this Issue 9/2010

Journal of Cancer Research and Clinical Oncology 9/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.